Disclosure notice in BioGaia

Sebastian Jahreskog, BioGaia's second largest shareholder, has announced that he has sold his shares in BioGaia to an endowment insurance. With this, he flagged a sale. The transaction only means a modified form of ownership and Sebastian Jahreskog intends to retain his holdings of BioGaia.

Latest press releases from BioGaia
2016-10-25 BioGaia AB Interim Management statement 1 January – 30 September 2016
2016-10-14 BioGaia’s probiotics to be launched in Kenya, Nigeria and Ghana
2016-08-17 BioGaia AB, Interim Report 1 January – 30 June 2016

For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health- enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the Nasdaq OMX Nordic Exchange Stockholm. www.biogaia.com.

BioGaia AB Box 3242. SE-103 64 STOCKHOLM Street address: Kungsbroplan 3A, Stockholm Telephone: +46 8 555 293 00, Corp. identity no. 556380-8723. www.biogaia.com.

About Us

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com If you need more information about BioGaia and our products please visit our website or download our press kit from: http://www.biogaia.com/press-material